| pubmed-article:16127286 | pubmed:abstractText | Since the p53 gene has been identified as a determinant of response to chemotherapy in ovarian carcinoma in previous studies, we investigated the significance of the p53 status in response to topotecan as second-line therapy. | lld:pubmed |
